“As diseases become more complex, the need for their quick and accurate diagnosis through testing will become more critical. This will lead to increased customer preference towards organised pathology lab networks. Over the last five years, Sterling Accuris have built a strong business in the markets we operate in and the growth capital infusion from a seasoned investor like Morgan Stanley Private Equity Asia will help the team accelerate the execution of our expansion plan. I also want to complement VedaCorp for their wonderful advise throughout the process”

“Sterling Accuris is one of the fastest growing technology enabled pathology lab chain in Gujarat with strong presence in Rajasthan, MP and Delhi. We are delighted to have Morgan Stanley Private Equity Asia on board as our growth partner. The investment in Sterling Accuris is a strong validation of our unique business model and the growth potential of the segments we operate in. The investment will enable us to expand our lab network to new geographies, build capabilities in digital technologies to grow our B2C service delivery and to develop new and innovative tests. I want to thank VedaCorp for working seamlessly with us during this successful deal closure”

“Sterling Accuris is a fast-growing diagnostic chain in West India that is led by a team of seasoned healthcare professionals. The Company has built a seamless approach to consolidate the standalone diagnostic labs / smaller chain of labs that are market leaders in each district and integrate them under the Sterling Accuris brand. With state-of-the-art national reference labs and digital solutions, the Company is well set to create a dominant position in West & North India.”